# ALTO-100 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/alto-100

> The next catalyst for ALTO-100, sponsored by Alto Neuroscience, Inc. (ANRO), is its primary completion, September 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ALTO-100 |
| Codes | ALTO-100 |
| Sponsor | Alto Neuroscience, Inc. (ANRO) https://sec-api.dev/companies/anro/catalysts |
| Indications | [Bipolar Disorder I or II With a Major Depressive Episode](https://sec-api.dev/indications/bipolar-disorder-i-or-ii-with-a-major-depressive-episode) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2024: topline data readout

- Status: completed, negative. Date confidence: month. Stage: 2.
- First seen 2024-11-12, last confirmed 2026-03-16.
- SEC Form 10-K (accession 0001999480-26-000002): "We have not yet succeeded and may not succeed in demonstrating efficacy for any product candidates in clinical trials (e.g., we reported negative topline results in October 2024 with regard to our Phase 2b trial of ALTO-100 in MDD) or in obtaining marketing approval thereafter." https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/alto-20251231.htm
- SEC Form 10-K (accession 0001999480-25-000025): "We have not yet succeeded and may not succeed in demonstrating efficacy for any product candidates in clinical trials (e.g., we reported negative topline results in October 2024 with regard to our Phase 2b trial of ALTO-100 in MDD) or in obtaining marketing approval thereafter." https://www.sec.gov/Archives/edgar/data/1999480/000199948025000025/alto-20241231.htm
- SEC Form 10-Q (accession 0001999480-24-000042): "In October 2024, we reported negative topline results from our Phase 2b clinical trial of ALTO-100 in MDD." https://www.sec.gov/Archives/edgar/data/1999480/000199948024000042/alto-20240930.htm
- SEC Form 10-Q (accession 0001999480-24-000042): "We have not yet succeeded and may not succeed in demonstrating efficacy for any product candidates in clinical trials (including in our Phase 2b trial of ALTO-100 in MDD, for which we reported negative topline results in October 2024) or in obtaining marketing approval thereafter." https://www.sec.gov/Archives/edgar/data/1999480/000199948024000042/alto-20240930.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2024-11-12, last confirmed 2026-05-12.
- Press release filed with the SEC (EX-99) (accession 0001999480-26-000001): "The Phase 2b trial of ALTO-100 in Bipolar Depression (BPD) is also ongoing, with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/exhibit991-earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001999480-25-000035): "- Late-stage programs advancing: Topline data expected from the Phase 2b trial of ALTO-300 in MDD in mid-2026 followed by the Phase 2b trial of ALTO-100 in bipolar depression in the second half of 2026 -" https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/exhibit991-earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001999480-24-000040): "•ALTO-100 is currently being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/exhibit991-earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001999480-25-000089): "•Enrollment in the randomized, double-blind, placebo-controlled Phase 2b trial remains ongoing with topline data expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/exhibit991-earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001999480-25-000075): "•Enrollment in the randomized, double-blind, placebo-controlled Phase 2b trial remains ongoing with topline data expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/exhibit991-earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001999480-25-000035): "•Enrollment in the randomized, double-blind, placebo-controlled Phase 2b trial remains ongoing with topline data expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/exhibit991-earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001999480-25-000024): "•Enrollment in the randomized, double-blind, placebo-controlled Phase 2b trial remains ongoing with topline data expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/exhibit991-earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-024814): "We look forward to reporting topline data in mid-2026." https://www.sec.gov/Archives/edgar/data/1999480/000119312525024814/d876505dex991.htm
- SEC Form 10-K (accession 0001999480-26-000002): "Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/alto-20251231.htm
- SEC Form 10-Q (accession 0001999480-25-000090): "Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948025000090/alto-20250930.htm
- SEC Form 10-Q (accession 0001999480-25-000076): "Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948025000076/alto-20250630.htm
- SEC Form 10-Q (accession 0001999480-25-000037): "Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1999480/000199948025000037/alto-20250331.htm

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Bipolar Disorder I or II With a Major Depressive Episode.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06656416 (ALTO-100 in Bipolar Disorder With Depression (BD-D)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Alto Neuroscience." https://clinicaltrials.gov/study/NCT06656416

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Bipolar Disorder I or II With a Major Depressive Episode.
- First seen 2026-05-13, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06656416 (ALTO-100 in Bipolar Disorder With Depression (BD-D)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Alto Neuroscience." https://clinicaltrials.gov/study/NCT06656416
- SEC Form 10-Q (accession 0001999480-26-000031): "Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in mid-2027." https://www.sec.gov/Archives/edgar/data/1999480/000199948026000031/alto-20260930.htm
- SEC Form 10-Q (accession 0001999480-26-000023): "Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in mid-2027." https://www.sec.gov/Archives/edgar/data/1999480/000199948026000023/alto-20260630.htm
- SEC Form 10-Q (accession 0001999480-26-000012): "Enrollment in this trial is ongoing, with a target of approximately 200 patients, and we expect to report topline data from the study in mid-2027." https://www.sec.gov/Archives/edgar/data/1999480/000199948026000012/alto-20260331.htm
- SEC Form 10-Q (accession 0001357459-26-000024): "Notwithstanding, ALTO-100 is being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in mid-2027." https://www.sec.gov/Archives/edgar/data/1357459/000135745926000024/pali-20260930.htm
- SEC Form 10-Q (accession 0001357459-26-000016): "Notwithstanding, ALTO-100 is being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in mid-2027." https://www.sec.gov/Archives/edgar/data/1357459/000135745926000016/pali-20260630.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/alto-100.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ALTO-100 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/alto-100

```bibtex
@misc{secapidev_pdufa_alto_100_20261116,
  title        = {ALTO-100 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/alto-100}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_alto_100_20261116","title":"ALTO-100 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/alto-100","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
